Is It Too Late to Buy GSK After a 46% Share Price Jump?

Core Viewpoint - GSK's stock has seen a significant increase of 44% over the past year, raising questions about whether it is still a viable investment opportunity after a recent pullback [1] Valuation - GSK's trailing P/E ratio is 14.6x, and it has a PEG ratio of 0.499, indicating it is growing faster than its valuation suggests [1] - The company offers a dividend yield of 3.27%, with a recent increase in dividend to 70p for 2026, representing a 6% rise [1] - The forward P/E ratio is projected at 21.41x, indicating that the market anticipates significant earnings growth, which introduces execution risk [1] Forward Catalysts - GSK's oncology sales increased by 42% to £567 million, and HIV sales grew by 11%, driven by strong performance in specialty medicines [1] - The company completed the acquisition of RAPT Therapeutics for $2.2 billion and 35Pharma for $950 million, enhancing its pipeline [1] - GSK aims for £40 billion in annual revenue by 2031, supported by new product launches and acquisitions [1] Risk and Entry - The stock recently pulled back nearly 8% from $59.13 to $54.51, presenting a potential buying opportunity [1] - Currency fluctuations pose a risk, as GSK reports in Sterling, with a potential negative impact of approximately 3% on sales and 6% on operating profit due to a strengthening pound [1] - Analyst consensus suggests a "Reduce" rating with an average target of $44.13, indicating a significant gap from current prices [1] Verdict - Current prices for GSK present a reasonable valuation, a growing dividend, and a robust pipeline, making it a potential buy for investors willing to navigate currency volatility [1]